Novartis' Cosentyx Phase 3 REPLENISH trial for polymyalgia rheumatica met primary and secondary endpoints, showing ...
Baricitinib can effectively treat polymyalgia rheumatica (PMR) without the use of oral glucocorticoids, according to results from a small, randomized, double-blind, placebo-controlled study. Among the ...
Novartis Cosentyx meets primary and all secondary endpoints in phase III trial in patients with polymyalgia rheumatica: Basel Thursday, October 23, 2025, 09:00 Hrs [IST] Novartis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback